Clinical Trial Update: Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for anlotinib in metastatic colorectal cancer (ALTER0703) across Phase 2 and Phase 3, with the study status noted as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Metastatic Colorectal Cancer | Phase 2, Phase 3 | Status: COMPLETED